Vanguard Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.68B Buy
16,595,978
+15,265
+0.1% +$7.82M 0.18% 86
2026
Q2
$8.24B Buy
16,580,713
+67,903
+0.4% +$30.1M 0.18% 91
2026
Q1
$7.37B Buy
+16,512,810
New +$7.7B 0.18% 93

Other funds holding VRTX

Vanguard Capital Management's VRTX Position: Q3 2026 in Review

Vanguard Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.09% in Q3 2026, buying an estimated $7.82M and bringing the position to 16,595,978 shares worth $8.68B. The position accounts for 0.18% of the portfolio, ranked #86.

Vanguard Capital Management first reported a position in VRTX in Q1 2026 and has held it in 3 quarters since. 1,676 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Vanguard Capital Management held 16,595,978 shares of Vertex Pharmaceuticals worth $8.68B as of Q3 2026.
  • Vanguard Capital Management bought 15,265 Vertex Pharmaceuticals shares in Q3 2026, an estimated $7.82M.
  • Vertex Pharmaceuticals made up 0.18% of Vanguard Capital Management's portfolio in Q3 2026, its #86 holding.
  • Vanguard Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 1,676 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.